.Pharmacolibrary.Drugs.ATC.N.N02AX07 .Pharmacolibrary.Drugs.ATC.N.N02AX07| name: | Oliceridine |
| ATC code: | N02AX07 | route: | intravenous |
| n-compartments | 2 |
Oliceridine is a synthetic opioid agonist that selectively targets the μ-opioid receptor as a G protein-biased agonist. It is used for the management of moderate to severe acute pain in adults where the pain is severe enough to require an intravenous opioid and for whom alternative treatments are inadequate. The drug was approved by the FDA in 2020 for intravenous use.
Pharmacokinetic parameters reported in healthy adult subjects after single intravenous administration.
Ni, Y, et al., & Yang, G (2024). Pharmacokinetics and Safety of Oliceridine Fumarate Injection in Chinese Patients with Chronic Non-Cancer Pain: A Phase I, Single-Ascending-Dose, Open-Label Clinical Trial. Drug design, development and therapy 18 2729–2743. DOI:10.2147/DDDT.S461416 PUBMED:https://pubmed.ncbi.nlm.nih.gov/38974123
Simons, P, et al., & Dahan, A (2023). Respiratory Effects of Biased Ligand Oliceridine in Older Volunteers: A Pharmacokinetic-Pharmacodynamic Comparison with Morphine. Anesthesiology 138(3) 249–263. DOI:10.1097/ALN.0000000000004473 PUBMED:https://pubmed.ncbi.nlm.nih.gov/36538359
Moss, L, et al., & Dahan, A (2023). Neurocognitive Effect of Biased µ-Opioid Receptor Agonist Oliceridine, a Utility Function Analysis and Comparison with Morphine. Anesthesiology 139(6) 746–756. DOI:10.1097/ALN.0000000000004758 PUBMED:https://pubmed.ncbi.nlm.nih.gov/37656771